Gena Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 20-04-2024
- Paid Up Capital ₹ 2.87 Cr
as on 20-04-2024
- Company Age 20 Year, 7 Months
- Last Filing with ROC 31 Mar 2020
- Open Charges ₹ 32.29 Cr
as on 20-04-2024
- Satisfied Charges ₹ 11.54 Cr
as on 20-04-2024
- Revenue -29.58%
(FY 2020)
- Profit 22.30%
(FY 2020)
- Ebitda 55.03%
(FY 2020)
- Net Worth -1.13%
(FY 2020)
- Total Assets -12.39%
(FY 2020)
About Gena Pharmaceuticals
- CIN/LLPIN
U24239WB2004PLC098504
- Company No.
098504
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
11 May 2004
- Date of AGM
28 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
North 24 Parganas, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Gena Pharmaceuticals Limited offer?
Gena Pharmaceuticals Limited offers a wide range of products and services, including Kidney Drugs, Potassium Magnesium Citrate Syrup, Pain Relief Drugs & Pharmaceuticals, Pain Reliever Gel, Allopathic Cough Syrup, Guaiphenesin Cough Syrup.
Who are the key members and board of directors at Gena Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abhishek Shukla  | Additional Director | 04-Jun-2019 | Current |
| Arabind Mishra | Additional Director | 30-Sep-2011 | Current |
| Vijaykumar Kanoria | Director | Current |
Financial Performance of Gena Pharmaceuticals.
Gena Pharmaceuticals Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 29.58% decrease. The company also saw a substantial improvement in profitability, with a 22.3% increase in profit. The company's net worth dipped by a decrease of 1.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gena Pharmaceuticals?
In 2019, Gena Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Gena Marketing Private LimitedActive 41 years 3 monthsAbhishek Shukla and Vijaykumar Kanoria are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Edelweiss Asset Reconstruction Company Limited Creation Date: 04 Oct 2008 | ₹12.66 Cr | Open |
Edelweiss Asset Reconstruction Company Limited Creation Date: 28 Aug 2008 | ₹12.66 Cr | Open |
Andhra Bank Creation Date: 03 Aug 2007 | ₹6.98 Cr | Open |
How Many Employees Work at Gena Pharmaceuticals?
Gena Pharmaceuticals has a workforce of 22 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gena Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gena Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
